Sichuan Kelun Pharmaceutical Co., Ltd.

002422

CNE100000PW7

Sichuan Kelun Pharmaceutical Co., Ltd. specializes in developing, manufacturing and marketing pharmaceuticals. Net sales break down by activity as follows: - manufacturing and sale of pharmaceutical products (98%). Net sales break down by family of products between injectable drugs (56.9%) and other (43.1%; tablets, capsules, granules, etc.); - other (2%). China accounts for 94.6% of net sales.

Sector

Pharmaceuticals

Calendar

2024-05-15 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Sichuan Kelun Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

33.95 CNY

Average target price

41.04 CNY

Spread / Average Target

+20.88%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SICHUAN KELUN PHARMACEUTICAL CO., LTD.	+16.87%	7.46B
ELI LILLY AND COMPANY	+29.68%	681B
NOVO NORDISK A/S	+25.07%	556B
JOHNSON & JOHNSON	-4.35%	361B
MERCK & CO., INC.	+17.65%	325B
ABBVIE INC.	+3.77%	285B
ASTRAZENECA PLC	+14.68%	235B
NOVARTIS AG	+4.71%	199B
ROCHE HOLDING AG	-12.43%	189B
PFIZER, INC.	-3.79%	157B

Other Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
33.95 ^CNY	+3.41%		+13.43%	+16.87%

Apr. 25	Sichuan Kelun Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023	CI
Apr. 25	Sichuan Kelun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Sichuan Kelun Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023	Apr. 24	CI
Sichuan Kelun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 24	CI
Sichuan Kelun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 10	CI
US FDA to Accelerate Review of Kelun Pharma Unit's Lung Cancer Drug	Mar. 12	MT
Kelun-Biotech Controlling Shareholder Ups Stake; Shares Rise 4%	Jan. 22	MT
Kelun Pharmaceutical's Olaparib Tablets Get Nod from Chinese Drug Regulator	Jan. 22	MT
Kelun Pharma Gets Registration Approval in China for Immune Thrombocytopenia Drug	Jan. 17	MT
Kelun Pharma Sees Up to 50% Jump in 2023 Profit	Jan. 15	MT
Kelun Pharma's Unit Gets US FDA's Orphan Drug Designation to A400	Nov. 28	MT
Kelun Pharmaceutical's Unit Gains Registration Certificate for Ceftazidime Avibactam Sodium/Sodium Chloride Injection	Nov. 01	MT
Sichuan Kelun Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-29	CI
Kelun Pharma Ends Cancer Drug Contract, Revises Partnership With Merck	23-10-23	MT
Global markets live: Foxconn, Roche, Eli Lilly, Chevron, Apple...	23-10-23
The good, the bad and the ugly	23-10-23
Merck discontinues some cancer drug development with China's Sichuan Kelun	23-10-23	RE
Kelun Pharma Unit Obtains Registration Approval in China for Bacterial Infection Drug	23-10-18	MT
Sichuan Kelun Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-29	CI
Sichuan Kelun Pharma to Start License Application Process For New Cancer Drug	23-08-15	MT
Kelun Pharma's Unit Gets Gadobutrol injection Certified	23-07-13	MT
Kelun Pharma Expects Up to 66% Jump in H1 Profit	23-07-05	MT
China's Sichuan Kelun-Biotech opens books for $208 million Hong Kong IPO - term sheet	23-06-28	RE
Kelun Pharma Registers GERD Drug in China	23-06-27	MT
Kelun Pharma Gets Nod for Nutritional Supplement	23-06-13	MT
Kelun Pharmaceutical Unit Kelun Biotech Begins Pre-Marketing Activities for Hong Kong IPO	23-06-05	MT
Sichuan Kelun Pharmaceutical Co., Ltd. Announces Cash Dividend on Share A for 2022, Payable on May 15, 2023	23-05-09	CI